Stay updated on Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.4.1 replaces v3.4.0 in the page header; this is a UI update with no impact on study content or user interactions.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded a glossary display option and updated small text labels (capitalization of QC criteria and FEAR Act data) with the revision bumped to v3.4.0 from v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedRevision v3.3.4 was added and v3.3.3 was removed. This appears to be a minor administrative update to the site versioning and does not change study content.SummaryDifference0.0%

- Check55 days agoChange Detected- The study's Locations section was updated to add numerous new sites across multiple countries and regions, and many existing locations were removed.SummaryDifference4%

- Check77 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.